The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use

Bibliography

• THYLEFORS B, NÉGREL AD: The global impact of glaucoma. Bull. WHO (1994) 72(3):323–326.
   PubMed Web of Science ®Google Scholar
• QUIGLEY HA: Number of people with glaucoma worldwide. Br. J. Ophthalmol. (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• HAEFLIGER JO: Risk factors associated with glaucoma. Klin. Monatsbl. Augenheilkd. (1997) 210(5):265–268.
   PubMed Web of Science ®Google Scholar
• GEORGOPOULOS G, ANDREANOS D, LIOKIS N et al.: Risk factors in ocular hypertension. Eur. J. Ophthalmol. (1997) 7(4):357–363.
   PubMedGoogle Scholar
• RITCH R, SHIELDS MB, KRUPIN T: Preface. In: The Glaucomas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis, USA (1996):xix-xx.
   Google Scholar
• EPSTEIN DL, KRUG JH, JR., HERTZMARK E, REMIS LL, EDELSTEIN DJ: A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology (1989) 96(10):1460–1467.
   Google Scholar
• KASS MA, GORDON MO, HOFF MR et al.: Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A random-ized, double-masked, long-term clinical trial. Arch. Ophthalmol. (1989) 107(11):1590–1598.
   PubMedGoogle Scholar
• MAO LK, STEWART WC, SHIELDS MB: Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol. (1991) 15(1111):51–55.
   Google Scholar
• COCKBURN DM: Does reduction of intraocular pressure (lOP) prevent visual field loss in glaucoma? Am. J. Optom. Phys. Opt. (1983) 60(8):705–711.
   PubMed Web of Science ®Google Scholar
• SCHULZER M, DRANCE SM, CARTER CM, BROOKS DE, DOUGLAS GR, LAU W: Biostatistical evidence for two distinct chronic open-angle glaucoma populations. Br. J. Ophthalmol. (1990) 74:196–200.
   PubMed Web of Science ®Google Scholar
• LAMPING KA, BELLOWS AR, HUTCHINSON BT, AFRAN SI. Long-term evaluation of initial filtration surgery. Ophthalmology (1986) 93(1):91–101.
   PubMed Web of Science ®Google Scholar
• MIGDAL C, GREGORY W, HITCHINGS R: Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthal-mology (1994) 101(10):1651–1656.
   PubMed Web of Science ®Google Scholar
• DAVID R: Changing therapeutic paradigms in glaucoma management. Exp. Opin. Invest. Drugs (1998) 7(7):1063–1086.
   PubMedGoogle Scholar
• LEVIN LA: An introduction to neuroprotection in glaucoma: mechanisms and implications. Eur. J. Ophthalmol. (1999) 9(S1):S7–S8.
   Google Scholar
• •A useful overview on the evolving neuroprotective therapeutic paradigm in glaucoma.
   Google Scholar
• QUIGLEY HA, ADDICKS EM, GREEN WR, MAUNEMEE AE: Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Am.J. Ophthalmol. (1981) 99:635–649.
   Google Scholar
• QUIGLEY HA, NICKELLS RW, KERRIGAN LA et al.: Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. (1995) 36:774–786.
   PubMed Web of Science ®Google Scholar
• NICKELLS RW: Retinal ganglion cell death in glaucoma: the how, the why and the maybe. J. Glaucoma (1996) 5:345–356.
   PubMed Web of Science ®Google Scholar
• OKISAKA S, MURAKAMI A, MIZUKAWA A, ITO J: Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn. J. Ophthalmol. (1997) 41(2):84–88.
   PubMed Web of Science ®Google Scholar
• CHAO DT, KORSMEYER SJ: Bc1-2 family: regulators of cell death. Ann. Rev. Immunol. (1998) 16:395–419.
   PubMed Web of Science ®Google Scholar
• •An excellent review on factors involved in the control of apoptosis.
   Google Scholar
• LEVIN LA: Intrinsic survival mechanisms for retinal ganglion cells. Eur.j Ophthalmol. (1999) 9(S1):S12–S16.
   Google Scholar
• JONES FL, JR., EKBERG NL: Exacerbation of asthma by timolol. N. Engl. J. Med. (1979) 301:270.
   PubMed Web of Science ®Google Scholar
• BRITMAN NA: Cardiac effects of topical timolol. N. Engl. J. Med. (1979) 300:566.
   PubMed Web of Science ®Google Scholar
• AHMAD S: Cardiopulmonary effects of timolol eyedrops. Lancet (1979) 2:1028.
   PubMed Web of Science ®Google Scholar
• JONES FL, EKBERG NL: Exacerbation of obstructive airway disease by timolol. JAMA (1980) 244:2730.
   PubMed Web of Science ®Google Scholar
• VAN BUSKIRK EM: Adverse reactions from timolol administration. Ophthalmology (1980) 87:447.
   PubMed Web of Science ®Google Scholar
• SCHOENE RB, MARTIN TR, CHARAN NB, FRENCH CL: Timolol-induced bronchospasm in asthmatic bronchitis. JANIA (1981) 245:1460–1461.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FT, MEYER SM: Systemic side effects from ophthalmic timolol and their prevention. J. Ocul. Pharmacol. (1987) 3:177–184.
   PubMedGoogle Scholar
• STEWART WC, CASTELLI WP: Systemic side effects oftopical beta-adrenergic blockers. Clin. Cardiol. (1996) 19:691–697.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS: Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin. Ther. (2000) 22(2):167–208.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the current safety profiles of availableocular hypotensive medications.
   Google Scholar
• DUCH S, DUCH C, PASTO L, FERRER P: Changes in depressive status associated with topical beta-blockers. Int. Ophthalmol. (1992) 16:331–335.
   PubMed Web of Science ®Google Scholar
• DIAMOND JP: Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging (1997) 11(5):352–360.
   PubMed Web of Science ®Google Scholar
• DIGGORY P, FRANKS W: Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol. (1996) 80(1):85–89.
   PubMed Web of Science ®Google Scholar
• KOLKER AE, MAY MM, DAY SE: Frequency of contraindi-cations to topical beta-blockers in a glaucoma popula-tion. Invest. Ophthalmol. Vis. Sci. (1999) 40:5514. Abstract.
   Google Scholar
• HARRIS LS, GREENSTEIN SH, BLOOM AF: Respiratory difficulties with betaxolol [letter]. Am. J. Ophthalmol. (1986) 102:274.
   PubMed Web of Science ®Google Scholar
• BALL S: Congestive heart failure from betaxolol. Case report. Arch. Ophthalmol. (1987) 105(3):320.
   PubMed Web of Science ®Google Scholar
• BROOKS AMV, GILLIES WE: Ocular beta-blockers in glaucoma management. Drugs Aging (1992) 2:208–221.
   PubMed Web of Science ®Google Scholar
• ALLEN RC, HERTZMARK E, WALKER AM et al.: A double-masked comparison of betaxolol vs. timolol in the treatment of open-angle glaucoma. Am. J. Ophthalmol. (1986) 101:535–541.
   Google Scholar
• WEINREB RN, VAN BUSKIRK EM, CHERNIAK R et al.: Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am. J. Ophthalmol. (1988) 106:162–167.
   PubMed Web of Science ®Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R, FOR THE INTERNA-TIONAL DORZOLAMIDE STUDY GROUP: A double-masked, randomized 1-year study comparing dorzola-mide (Trusopt), timolol and betaxolol. Arch. Ophthalmol. (1995) 113(8):1009–1016.
   PubMed Web of Science ®Google Scholar
• SILVER LH: Clinical efficacy and safety of brinzolarnide (Azoptr"), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. (1998) 126:400–408.
   PubMed Web of Science ®Google Scholar
• WILENSKY JT: The role of brimonidine in the treatment of open-angle glaucoma. Surv. Ophthalmol. (1996) 41\(Suppl. 1):S3–S7.
   Google Scholar
• CANTOR BL, BURKE J: Brimonidine. Exp. Opin. Invest. Drugs (1997) 6(8):1063–1083.
   PubMedGoogle Scholar
• ••An excellent review on the preclinical pharmacology andclinical development of brimonidine 0.2% for the treatment of ocular hypertension and glaucoma.
   Google Scholar
• MILLIGAN G, SVOBODA P, BROWN CM: Why are there so many adrenoceptor subtypes? Biochem. Pharmacol. (1994) 48(6):1059–1071.
   Web of Science ®Google Scholar
• GIESER SC, JUZYCH M, ROBIN AL et al.: Clinical pharma-cology of adrenergic drugs. In: The Glaucomas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St Louis, USA (1996):1425–1448.
   Google Scholar
• TORIS CB, CAMRAS CB, YABLONSKI ME: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. (1995) 113:1514–1517.
   PubMed Web of Science ®Google Scholar
• BURKE J, SCHWARTZ M: Preclinical evaluation of brimonidine. Surv. Ophthalmol. (1996) 41(Suppl.):59–518.
   Google Scholar
• YOLES E, SCHWARTZ M: Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv. Ophthal. (1998) 42(4):367–372.
   PubMed Web of Science ®Google Scholar
• WHEELER LA, LAI R, WOLDEMUSSIE E: From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur. J. Ophthalmol. (1999) 9\(Suppl. 1):517–S21.
   Google Scholar
• MORRISON JC: Side effects of a-adrenergic agonists. J. Glaucoma (1995) 4\(Suppl. 1):S36–S38.
   Google Scholar
• MUNK SA, GLUCHOWSKI C, DOLBY L et al.: Analogs of UK-14,304 as alpha2-adrenoceptor agonists. Twist and agent polarity as design elements. Bioorg. Med. Chem. Lett. (1994) 4:459–462.
   Web of Science ®Google Scholar
• HODAPP E, KOLKER A, KASS M et al.: The effect of topicalclonidine on intraocular pressure. Arch. Ophthalmol. (1981) 99:1208–1211.
   PubMed Web of Science ®Google Scholar
• MUNK SA, WIESE A, THOMPSON CD et al.: Oxidationpotential and allergic response of a2-agonists. Invest. Ophthalmol. Vis. Sci. (1996) 37:S382. Abstract 3839.
   Google Scholar
• ATLAS D, SABOL SL: Interaction of clonidine and clonidine analogues with alpha-adrenergic receptors of neuroblastoma X glioma hybrid cells and rat brain: Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved. comparison of ligand binding with inhibition of adenylate cyclase. Eur.J. Biochem (1981) 113(3):521–529.
   Google Scholar
• STEER ML, ATLAS D: Interaction of clonidine andclonidine analogs with human platelet alpha 2-adrenergic receptors. Biochim. Biophys. Acta. (1982) 714(3):389–394.
   PubMed Web of Science ®Google Scholar
• MUNK SA, HARCOURT D, ARASASINGHAM P et al.: Analogs of UK 14,304: structural features responsible for a2 adrenoceptor activity. Bioorg. Med. Chem. Lett. (1995) 5(19:1745–1750.
   Google Scholar
• THOMPSON CD, MACDONALD TL, GARST ME et al. Mechanisms Mechanisms of adrenergic agonist induced allergy: bioactivation and antigen formation. Exp. Eye Res (1997) 64(5)767–773.
   Google Scholar
• CHANDLER ML, DESANTIS L: Studies of p-amino clonidine as a potential antiglaucoma agent. Invest. Ophthal. Vis. Sci. (1985) 26(53):227. Abstract 93.
   Google Scholar
• FAHRENBACH WH, BACON DR, VAN BUSKIRK EM: Vasoactive drug effects on the uveal vasculature of the rabbit: a corrosion casting study. Invest. Ophthalmol. Vis. Sci. (1989) 30(Suppl.):100. Abstract.
   Google Scholar
• CARDAKLI F, SMYTHE B, EISELE J et al.: Effect of chronicapraclonidine treatment on intraocular pressure in advanced glaucoma. J. Glaucoma (1992) 1:271–278.
   PubMedGoogle Scholar
• NAGASUBRAMANIAN S, HITCHINGS RA, DE-MAILLYP etal.: Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology (1993) 100.1318–1323.
   Google Scholar
• ROBBIN AL: Questions concerning the role of apraclo-nidine in the management of glaucoma. Arch. Ophthalmol. (1995) 113:712–714.
   PubMed Web of Science ®Google Scholar
• ARAUJO SV, BOND JB, WILSON RP et al.: Long term effectof apraclonidine. Br. J. Ophthalmol. (1 9 9 5) 79(12):1098–1101.
   Google Scholar
• CAMBRIDGE D: UK-14,304, a potent and selective alpha-2-agonist for the characterization of alpha-adrenoceptor subtype. Eur. J. Pharmacol (1981) 72:413–415.
   PubMed Web of Science ®Google Scholar
• DERICK RJ, ROBIN AL, WALTERS TR et al.: Brimonidinetartrate: a one month dose response study. Ophthal-mology (1997) 104:131–136.
   PubMed Web of Science ®Google Scholar
• ROBIN AL. Short-term effects of unilateral 1% apraclo-nidine therapy. Arch. Ophthalmol. (1988) 106(7):912–915.
   PubMedGoogle Scholar
• LIN SL, LIANG SS. Evaluation of adverse reactions ofaponidine hydrochloride ophthalmic solution. J. Ocul. Pharmacol. Ther. (1995) 11(3):267–278.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS, HORWITZ B, CHOPLIN NT et al.: A 1-yearstudy of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch. Ophthalmol. (1997) 115:847–852.
   PubMed Web of Science ®Google Scholar
• •Phase III registration study number 1 of 2.
   Google Scholar
• SCHUMAN JS: Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv. Ophthalmol. (1996) 41:S27–S37.
   Google Scholar
• •Combined analysis of the 12-month data from registration study 1 [67] and the 6-month data from registration study 2 [69].
   Google Scholar
• LE BLANC RP, FOR THE BRIMONIDINE STUDY GROUP II:
   Google Scholar
• -month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in glaucoma or ocular hyperten-sion patients. Ophthalmology (1998) 105(10):1960–1967.
   Google Scholar
• •Registration study number 2 of 2.
   Google Scholar
• KATZ 41, FOR THE BRIMONIDINE STUDY GROUPS 1 & 2: Twice-daily brimonidine tartrate 0.2% vs. timolol 0.5%: 1-year results in glaucoma patients. Am. J. Ophthalmol. (1999) 127:20–26.
   Google Scholar
• •Combined analysis of the 12-month study results from both one-year clinical trials [67,69].
   Google Scholar
• CHIEN D-S, HOMSY JJ, GLUCHOWSKI C et al.: Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342 and clonidine in rabbit eyes. Curr. Eye Res. (1990) 9(11):1051–1059:
   PubMed Web of Science ®Google Scholar
• CHIEN D-S, RICHMAN J, ZOLEZIO H: Drug distribution of brimonidine in albino and pigmented rabbit eyes. Pharm. Res. (1992) 9(Suppl.):5336. Abstract PPDM 8320.
   Google Scholar
• ACHEAMPONG AA, SHACKLETON M, TANG-LIU DD-S: Comparative ocular pharmokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab. Dispos. (1995) 23(7):708–712.
   PubMed Web of Science ®Google Scholar
• BURKE J, MANLAPAZ C, KHARLAMB A et al.: Therapeutic use of a2-adrenoreceptor agonists in glaucoma. In: a 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications. Lanier S, Limbird L (Eds.), Harwood Academic Publishers, Reading, UK (1996):179–187.
   Google Scholar
• BARNEBEY HS, ROBIN AL, ZIMMERMAN TJ et al.: The efficacy of brimonidine in decreasing elevations of intraocular pressure after laser trabeculoplasty. Ophthalmology (1993) 100:1083–1088.
   PubMed Web of Science ®Google Scholar
• DAVID R, SPAETH GL, CLEVENGER CE eta/.: Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch. Ophthalmol. (1993) 113:1387–1390.
   Google Scholar
• NORDLUND JR, PASQUALE LR, ROBIN AL et al.: The cardiovascular, pulmonary and ocular hypotensive effects of 0.2% brimonidine. Arch. Ophthalmol. (1995) 113:77–83.
   Google Scholar
• WALTERS TR: Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure; a review of safety, efficacy, dose response anddosing studies. Surv.Ophthalmol. (1996)41:S19–S26.
   PubMed Web of Science ®Google Scholar
• TORTS CB, CAMRAS CB, YABLONSKI ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. (1999) 128(1):8–14.
   PubMed Web of Science ®Google Scholar
• SERLE JB: A comparison of the safety and efficacy oftwice daily brimonidine 0.2% versus betaxolol 0.25% Exp. Opin. Pharmacother. (2000)1(4) in subjects with elevated intraocular pressure. Surv. Ophthalmol. (1996) 41\(Suppl 1):S39–S47.
   Google Scholar
• MELAMED S, DAVID R: Ongoing assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin. Ther. (2000) 22(1):103–111.
   PubMed Web of Science ®Google Scholar
• •Third-year results from the extension of study 2 [69].
   Google Scholar
• ABELSON MB, CHAPIN M, BATOOSINGH A, CHEN K, YORK J: A retrospective examination of drug-induced allergy to Alphagan and a proposal for anew reporting system. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):5515. Abstract 2718.
   Google Scholar
• BUTLER PJ, JONES B: Incidence of characteristics of allergic reaction to apraclonidine 0.5%. Invest. Ophthalmol. Vis. Sci. (1996) 37(3):5201. Abstract 936.
   Google Scholar
• SHIN DH, GLOVER BK, CHA SC, KIM YY, KIM C, NGUYEN KD: Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am. J. Ophthalmol. (1999) 127(5):511–515.
   PubMed Web of Science ®Google Scholar
• GORDON RN, LEIBMANN JM, GREENFIELD DS, LAMA P, RITCH R: Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye (1998) 12:697–700.
   PubMed Web of Science ®Google Scholar
• SCHIFFMAN R, JAVITT J: Cinical success and quality of life with brimonidine 0.2% or timolol 0.5% used b.i.d. in glaucoma or ocular hypertension: a randomized clinical trial. J. Glaucoma (2000) (In Press).
   Google Scholar
• JAVITT J, GOLDBERG I: Brimonidine 0.2% versus betaxolol 0.25% as measured by the clinical success rate and quality of life effects in patients with glaucoma or ocular hypertension. J. Glaucoma (2000) (In Press).
   Google Scholar
• WANG F, JAVITT JC, ROWE M, MENG K: Measuring theimpact of glaucoma and its treatment on quality of life: the Glaucoma Disability Index. Invest. Ophthalmol. Vis. Sci. (1996) 37(3):5643. Abstract 2982.
   Google Scholar
• LEE DA. Efficacy of brimonidine as replacementtherapy in patients with open-angle glaucoma or ocular hypertension. Clin. Ther. (2000) 22(1):53–65.
   PubMed Web of Science ®Google Scholar
• NETLAND P, ABELSON MB, WELCH DL, CHAPIN MJ, LATINA M: A two month evaluation of Alphagan alone compared to patient's previous two line therapy. J. Glaucoma (1998) 8(Suppl.):514. Abstract.
   Google Scholar
• TRAVERSO CE, FOR THE BRIMONIDINE ADDITIVITY STUDY GROUP I: Additivity of brimonidine 0.2% b.i.d. or pilocarpine 2% t.i.d. to beta-blocker monotherapy. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S480. Abstract 2199.
   Google Scholar
• SIMMONS ST: Comparison of the efficacy and tolerability of Alphagan and Trusopt as adjunct therapy with beta-blockers in patients with chronic open-angle glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. (2000) 41(4). Abstract 4001.
   Google Scholar
• SAMUELSON T, SIMMONS ST: Efficacy and tolerability ofAlphagan versus Xalatan as adjunct therapy in chronic open-angle glaucoma or ocular hypertension patients uncontrolled on beta-blockers alone. Invest. Ophthalmol. Vis. Sci. (2000) 41(4). Abstract.
   Google Scholar
• SIMMONS ST, SAMUELSON TW: Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin. Ther. (2000) 22(4). (In Press).
   Google Scholar
• BARNES SD, CAMPAGNA JA, DIRKS MS, DOE EA: Controlof intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology (1999) 106(10):2033–2037.
   Google Scholar
• CHEVRIER RL, ASSALIAN A, DUPERRE J, LESK MR: Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg. Lasers (1999) 30(3):199–204.
   Google Scholar
• LARK K, PASHA AS, YAN X, EDWARD DP: The effect oflatanoprost and brimonidine on rabbit subconjunc-tival fibroblast. J. Glaucoma (1999) 8(1):72–76.
   PubMed Web of Science ®Google Scholar
• YOUNG TL, HIGGINBOTHAM EJ, ZOU X, FARBER MD: Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology (1990) 97:1423–1427.
   PubMed Web of Science ®Google Scholar
• MATER C, STEINBERG GK, SUN GH et al.: Neuroprotec-don by the alpha-2-adrenoreceptor agonist dexmede-tomidine in a focal model of cerebral ischemia. Anesthesiology (1993) 79:306–312.
   PubMed Web of Science ®Google Scholar
• REIS DJ, REGUNATHAN S, MEELEY MP: Imidazole receptors and clonidine displacing substance in relationship to control of blood pressure, neuropro-tection and adrenomedullary secretion. Am. J. Hypertens. (1992) 5:518-57S.
   Google Scholar
• KENT A, NUSSDORF J, FELLOWS D, SMALL D, DAVID R: Brimonidine concentration in human vitreous following topical Alphagan treatment. Proceedings of the American Glaucoma Society (2000). Abstract.
   Google Scholar
• MITCHELL CK, NGUYEN CK, FELDMAN RM: Neuroprotec-don of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):5261. Abstract 1187.
   Google Scholar
• KELLY M, JOLLIMORE CA, HOOPER ML et al.: Brimonidine decreases excitotoxic cell death in retinal cultures. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):5481. Abstract.
   Google Scholar
• DREYER EB: A proposed role for excitotoydcity in glaucoma. J. Glaucoma (1998) 7(1):62–67.
   PubMed Web of Science ®Google Scholar
• VOLES E, WHEELER LA, SCHWARTZ M: Alpha 2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. (1999) 40(1):65–73.
   PubMed Web of Science ®Google Scholar
• HASSON D, LAI RK, CHUN T, WHEELER L: Functional protection of rat retina from ischemic injury by brimonidine. Soc. Neurosci. (1997) 23(1–2):168. Abstract.
   Google Scholar
• AHMED F, HEGAZY K, CHAUDHARY P, SHARMA SC: Neuroprotective effect of brimonidine on adult retinal ganglion cells after increased intraocular pressure. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):5265. Abstract. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• LAI RK, CHUN TY, HASSON DW et al.: Brimonidine protects photoreceptors and visual function after light damage. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S876. Abstract 4066.
   Google Scholar
• ERVIN CS, WOHARBREBBI A, IANNACCONE A, JABLONSKI MM: Brimonidine rescues photoreceptors from degeneration induced by retinal pigment epithe-lium removal in vitro. Invest. Ophthalmol. Vis. Sci. (1999) 40(4):5160. Abstract.
   Google Scholar
• WEN R, CHENG T, LI Y, GAO W, STEINBERG RH: Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J. Neurosci. (1996) 16(19):5986–5992.
   PubMed Web of Science ®Google Scholar
• SIEVERS J, HAUSMANN B, UNSICKER K, BERRY M: Fibroblast growth factors promote the survival of adult rat retinal ganglion cells after transection of the optic nerve. Neurosci. Lett. (1987) 76:157–162.
   PubMed Web of Science ®Google Scholar
• ZHANG C, TAKAHASHI K, LAM TT, TSO MO: Effects of basic fibroblast growth factor in retinal ischemia. Invest. Ophthalmol. Vis. Sci. (1994) 35(8):3163–3168.
   PubMed Web of Science ®Google Scholar
• PENG M, YIWEN L, ZHIJUN L, LIU C, LATTIES A, WEN R: Alpha-2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Mueller cells in vivo. Invest. Ophthalmol. Vis. Sci. (1998) 39:1721–1726.
   PubMed Web of Science ®Google Scholar
• NICHOLS AJ: Functions mediated by a-adrenoceptors. In: a Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology. Ruffolo RR (Ed.), Karger New York, USA (1991):115–179.
   Google Scholar
• SPADA CS, NIEVES AL, BURKE JA et al.: Comparative effects of a2-adrenoceptor agonists on microvessel caliber in human retinal tissue In: Sixth World Congress for Microcirculation. Messmer K, Kubler W (Eds.), (1996):511–514.
   Google Scholar
• SPADA CS, NIEVES AL, BURKE JA et al.: Comparative effects of brimonidine, p-aminoclonidine and clonidine on arteriolar caliber in human retinal tissue. Invest. Ophthalmol. Vis. Sci. (1995) 36:S1041. Abstract 4817.
   Google Scholar
• JOYNER WL, GILMORE JP: Tissues grafted into the hamster cheek pouch. In: Physical Techniques in Biology and Medicine Chapter 1, Volume X. Baker CH, Nastok WL (Eds.), Academic Press, New York, USA (1986):3–17.
   Google Scholar
• LACHKAR Y, MIGDAL C, DHANJIL S: Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch. Ophthalmol. (1999) 116(12):1591–1594.
   Google Scholar
• CARLSSON AM, CHAUHAN BC, LEE AA, LEBLANC RP: The effect of brimonidine tartrate (0.2%) on retinal blood flow in patients with ocular hypertension. Am. J. Ophthalmol. (2000) 129(3):297–301.
   Google Scholar
• KANZOW U, PILLUNAT LE, BOHM AG, KATZ AB, RICHARD G: Scanning laser doppler flowmetry after topical brimonidine administration. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):5271. Abstract 1235.
   Google Scholar
• MASTROPASQUA L, CIANCAGLINI M, CARPINETO P et al.: Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients. Acta. Ophthalmol. Scand. Suppl. (1998) 227:36.
   Google Scholar
• KORSCH E, GROTE A, SEYBOLD M, SODITT V: Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur. J. Pediatr. (1999) 158(8):685.
   PubMed Web of Science ®Google Scholar
• CARLSEN JO, ZABRISKIE NA, KWON YH, BARBE ME, SCOTT WE: Apparent central nervous system depres-sion in infants after the use of topical brimonidine. Am. J. Ophthalmol. (1999) 128(2):255–256.
   PubMed Web of Science ®Google Scholar
• RODIER PM: Developing brain as a target of toxicity. Environ. Health Perspect. (1995) 6(Suppl.):73–76.
   Google Scholar
• TANAKA E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharm. Ther (1998) 23(4):247–255.
   PubMed Web of Science ®Google Scholar